Total Payments
$18,234
2024 Payments
$5,467
Companies
37
Transactions
141
Medicare Patients
4,324
Medicare Billing
$2.0M
Payment Breakdown by Category
Consulting$13,868 (76.1%)
Food & Beverage$3,906 (21.4%)
Education$443.29 (2.4%)
Travel$17.37 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $13,868 | 6 | 76.1% |
| Food and Beverage | $3,906 | 122 | 21.4% |
| Education | $443.29 | 12 | 2.4% |
| Travel and Lodging | $17.37 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $4,323 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,556 | 5 | $0 (2022) |
| GENZYME CORPORATION | $3,531 | 11 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $3,530 | 1 | $0 (2017) |
| Genentech USA, Inc. | $348.79 | 17 | $0 (2020) |
| Amgen Inc. | $288.33 | 8 | $0 (2020) |
| PFIZER INC. | $275.22 | 18 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $243.22 | 14 | $0 (2022) |
| BeiGene USA, Inc. | $220.41 | 2 | $0 (2023) |
| GlaxoSmithKline, LLC. | $215.16 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,467 | 10 | GENZYME CORPORATION ($2,921) |
| 2023 | $535.51 | 5 | GENZYME CORPORATION ($235.72) |
| 2022 | $2,005 | 6 | Novartis Pharmaceuticals Corporation ($1,700) |
| 2021 | $2,455 | 8 | AstraZeneca Pharmaceuticals LP ($2,060) |
| 2020 | $2,160 | 19 | Novartis Pharmaceuticals Corporation ($1,820) |
| 2019 | $773.51 | 43 | PFIZER INC. ($117.96) |
| 2018 | $905.82 | 44 | Genentech USA, Inc. ($224.18) |
| 2017 | $3,932 | 6 | SANOFI-AVENTIS U.S. LLC ($3,530) |
All Payment Transactions
141 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.00 | General |
| Category: Hematology | ||||||
| 10/23/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: CELLT | ||||||
| 08/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $2,675.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $17.37 | General |
| Category: Oncology | ||||||
| 08/13/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $56.39 | General |
| Category: SURGERY | ||||||
| 06/03/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| Category: Oncology | ||||||
| 04/26/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $103.76 | General |
| Category: Oncology | ||||||
| 02/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Education | In-kind items and services | $16.40 | General |
| Category: ONCOLOGY | ||||||
| 01/18/2024 | ImmunoGen, Inc. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $86.51 | General |
| Category: ONCOLOGY | ||||||
| 08/30/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $136.56 | General |
| Category: Oncology | ||||||
| 08/15/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $30.72 | General |
| Category: ONCOLOGY | ||||||
| 04/19/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 03/03/2023 | JAZZ PHARMACEUTICALS INC. | DEFITELIO (Drug) | Food and Beverage | In-kind items and services | $144.07 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 02/21/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $99.16 | General |
| Category: Oncology | ||||||
| 11/30/2022 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $98.74 | General |
| Category: Oncology | ||||||
| 06/02/2022 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $72.68 | General |
| Category: ONCOLOGY | ||||||
| 05/12/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 04/15/2022 | Novartis Pharmaceuticals Corporation | TABRECTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: ONCOLOGY | ||||||
| 02/24/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $95.41 | General |
| Category: Oncology | ||||||
| 01/04/2022 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $25.52 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2021 | GENZYME CORPORATION | ELITEK (Biological) | Food and Beverage | In-kind items and services | $117.10 | General |
| Category: Oncology | ||||||
| 11/30/2021 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $15.50 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $117.32 | General |
| Category: Oncology | ||||||
| 10/21/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $1,942.50 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 1,245 | 55,286 | $4.4M | $980,018 |
| 2022 | 29 | 1,099 | 17,073 | $1.4M | $379,054 |
| 2021 | 29 | 1,081 | 20,801 | $1.4M | $388,832 |
| 2020 | 25 | 899 | 4,861 | $1.1M | $285,252 |
Total Patients
4,324
Total Services
98,021
Medicare Billing
$2.0M
Procedure Codes
116
All Medicare Procedures & Services
116 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 19 | 13,400 | $2.6M | $580,033 | 22.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 33 | 5,040 | $418,444 | $93,601 | 22.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 99 | 318 | $213,715 | $47,396 | 22.2% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 20 | 552 | $175,510 | $39,314 | 22.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 12 | 15,700 | $164,257 | $36,628 | 22.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 64 | 254 | $153,876 | $30,656 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 152 | 287 | $138,076 | $28,676 | 20.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 93 | 289 | $81,981 | $18,903 | 23.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 88 | 127 | $79,961 | $18,231 | 22.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 15 | 124 | $75,229 | $16,527 | 22.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 54 | 154 | $63,105 | $15,295 | 24.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 98 | 174 | $59,348 | $9,224 | 15.5% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 15 | 6,240 | $38,129 | $8,542 | 22.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 48 | 48 | $39,396 | $8,518 | 21.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 24 | 93 | $27,395 | $5,506 | 20.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 41 | 68 | $32,601 | $5,500 | 16.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 41 | 272 | $25,272 | $3,806 | 15.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 21 | 46 | $12,378 | $2,421 | 19.6% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 72 | $9,672 | $2,222 | 23.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 68 | 145 | $11,696 | $1,794 | 15.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 15 | 68 | $9,107 | $1,734 | 19.0% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 21 | 39 | $4,257 | $978.01 | 23.0% |
| J9267 | Injection, paclitaxel, 1 mg | Office | 2023 | 12 | 9,411 | $4,366 | $977.79 | 22.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 15 | 35 | $5,135 | $918.86 | 17.9% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2023 | 14 | 377 | $3,303 | $739.67 | 22.4% |
About Dr. Benjamin Leach, M.D
Dr. Benjamin Leach, M.D is a Hematology & Oncology healthcare provider based in Mission Hills, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2012. The National Provider Identifier (NPI) number assigned to this provider is 1497026140.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Leach, M.D has received a total of $18,234 in payments from pharmaceutical and medical device companies, with $5,467 received in 2024. These payments were reported across 141 transactions from 37 companies. The most common payment nature is "Consulting Fee" ($13,868).
As a Medicare-enrolled provider, Leach has provided services to 4,324 Medicare beneficiaries, totaling 98,021 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 116 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Mission Hills, CA
- Active Since 01/25/2012
- Last Updated 11/11/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1497026140
Products in Payments
- LYNPARZA (Drug) $4,305
- JEVTANA (Drug) $3,530
- SARCLISA (Biological) $3,378
- MEKINIST (Drug) $1,800
- TABRECTA (Drug) $1,700
- ZEJULA (Drug) $271.07
- BRUKINSA (Drug) $220.41
- TECENTRIQ (Biological) $204.93
- OPDIVO (Biological) $176.54
- GILOTRIF (Drug) $168.25
- Yescarta (Drug) $150.00
- ADCETRIS (Biological) $147.02
- DEFITELIO (Drug) $144.07
- CYRAMZA (Drug) $128.43
- ELITEK (Biological) $117.10
- Kyprolis (Biological) $112.69
- Perjeta (Biological) $88.11
- ELAHERE (Drug) $86.51
- Braftovi (Drug) $80.51
- KEYTRUDA (Biological) $66.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Mission Hills
Sarmen Sarkissian, M.d, M.D
Hematology & Oncology — Payments: $528,802
Hematology & Oncology $528,802
Albert Dekker, Md, MD
Hematology & Oncology — Payments: $36,150
Hematology & Oncology $36,150
Rafid Kouz, Md, MD
Hematology & Oncology — Payments: $21,418
Hematology & Oncology $21,418
Sarah Ali, Md, MD
Hematology & Oncology — Payments: $12,472
Hematology & Oncology $12,472
Dilprit Bagga, Md, MD
Hematology & Oncology — Payments: $9,698
Hematology & Oncology $9,698
Gagandeep Brar, Md, MD
Hematology & Oncology — Payments: $4,098
Hematology & Oncology $4,098